跳至主要内容
临床试验/NCT03115502
NCT03115502已完成不适用

Hemodynamic Changes and Vascular Tone Control After Bariatric Surgery. Prognostic Value Regarding Hypertension and Target Organ Damage

Parc de Salut Mar1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2013年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
50
试验地点
1
主要终点
Mean changes 24h-aortic systolic-blood pressure (SBP) measured in mmHg

研究概览

简要总结

Obese patients have increased cardiovascular risk and target organ damage (TOD) as compared to people with normal weight. Weight loss reduces cardiovascular risk and TOD. These changes have been associated mainly to changes in inflammatory and pro-atherogenic markers. Office peripheral blood pressure (BP) appears to decrease after bariatric surgery, but information on changes in 24h-ambulatory-BP-monitoring (24h-ABPM) and central-BP(cBP), or about the possible role of renin-angiotensin-aldosterone (RAAS), serotonin(STS) and endocannabinoid(ECS) systems is scarce. Our hypothesis is that the hemodynamic changes mediated by alterations in the RAAS, STS and ECS after weight loss are also responsible for the reduction of TOD.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged 18 - 65 years,
  • who have medical indication for treatment with bariatric surgery and agreeing to undergo the intervention,with
  • given informed consent

排除标准

  • Unmeeting the above Inclusion Criteria.

结局指标

主要结局

Mean changes 24h-aortic systolic-blood pressure (SBP) measured in mmHg

时间窗: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.

次要结局

  • Mean changes in peripheral- 24h, daytime and nighttime blood pressure estimates measured in mmHg(From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.)
  • Mean change in arterial stiffness parameters (I)(From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.)
  • Mean change in Left atrium diameter(From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.)
  • Mean changes in aortic- 24h, daytime and nighttime blood pressure estimates others than 24h systolic blood pressure measured in mmHg(From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.)
  • Mean change in office blood pressure estimates measured in mmHg(From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.)
  • Mean change in left ventricular remodeling index(From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.)
  • Mean change in the serotonergic system components(From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.)
  • Mean change in arterial stiffness parameters (II)(From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.)
  • Mean change in Left ventricular mass index(From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.)
  • Mean change in Ejection fraction(From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.)
  • Mean change in carotid intima-media thickness measured in mm(From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.)
  • Mean change in biochemical parameters measured in mg/dl or mmol/L(From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.)
  • Mean change in the components of the renin-angiotensin system(From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.)
  • Mean change in the components of the endocannabinoid system(From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.)
  • Mean change in pro-atherosclerotic markers(From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.)

研究者

发起方
Parc de Salut Mar
申办方类型
Other
责任方
Principal Investigator
主要研究者

Anna Oliveras

Head of Hypertension & Vascular Risk Unit. Nephrology Department

Parc de Salut Mar

研究点 (1)

Loading locations...

相似试验